



## Cancer Control Program Symptom Intervention Committee

200 First Street, SW  
Rochester, MN 55905  
P: 507-266-9202  
F: 507-284-1803

[www.allianceforclinicaltrialsinoncology.org](http://www.allianceforclinicaltrialsinoncology.org)

Charles L. Loprinzi, M.D.  
Chair

### Agenda Symptom Intervention Committee Meeting Saturday May 16, 2015 9:00-11:00 AM CST

**Meeting available by teleconference: Dial 800-501-8979 Access Code: 7181781**

<b>Committee Leadership Members:</b>		
Charles L. Loprinzi, MD	Chair	<a href="mailto:cloprinzi@mayo.edu">cloprinzi@mayo.edu</a>
Deb Barton, RN, PhD	Co-vice Chair	<a href="mailto:debbartn@med.umich.edu">debbartn@med.umich.edu</a>
Andrew L. Himmelstein, MD	Co-vice Chair	<a href="mailto:ahimmelstein@cbg.org">ahimmelstein@cbg.org</a>
Kathryn J. Ruddy, MD	Co-vice Chair	<a href="mailto:Ruddy.Kathryn@mayo.edu">Ruddy.Kathryn@mayo.edu</a>
Ellen L. Smith, PhD	Co-vice Chair	<a href="mailto:ellenls@med.umich.edu">ellenls@med.umich.edu</a>
Jan C. Buckner, MD	CCP Program Director	<a href="mailto:buckner.jan@mayo.edu">buckner.jan@mayo.edu</a>
Jacqueline M. Lafky, MS	CCP Program Manager	<a href="mailto:lafky.jacqueline@mayo.edu">lafky.jacqueline@mayo.edu</a>
Deborah Dickman	CCP Administrative Assistant	<a href="mailto:dickman.deborah@mayo.edu">dickman.deborah@mayo.edu</a>

- I. **New Concepts**
- II. **Status of Concepts**
- III. **Recently Opened Protocols**
- IV. **Other Open Studies**
- V. **Associated Pilot Trials**
- VI. **Studies Recently Closed, Being Analyzed**
- VII. **Abstracts Since November 2014**
- VIII. **Publications Since November 2014**
- IX. **Other Business**

**Primary Sponsoring Committee**

**Manuscripts (6):**

- Barton, D. L., G. Thanarajasingam, J. A. Sloan, B. Diekmann, J. Fuloria, L. A. Kottschade, A. P. Lyss, A. J. Jaslowski, M. A. Mazurczak, S. C. Blair, S. Terstriep and C. L. Loprinzi. Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). *Cancer*. 2014 Nov 15; 120(22): 3575-3583. PubMed PMID: 25043153; PubMed Central: PMC4221473. (Study ID: N08C3)
- Beutler, A. S., A. A. Kulkarni, R. Kanwar, C. J. Klein, T. M. Therneau, R. Qin, M. S. Banck, G. K. Boora, K. J. Ruddy, Y. Wu, R. L. Smalley, J. M. Cunningham, N. A. Le-Lindqwister, P. Beyerlein, G. P. Schroth, A. J. Windebank, S. Zuchner and C. L. Loprinzi. Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy. *Ann Neurol*. 2014 Nov; 76(5): 727-737. PubMed PMID: 25164601; PubMed Central: PMCTBD. (Study ID: N08C1)
- Dueck, A. C., J. Singh, P. Atherton, H. Liu, S. Hines, C. L. Loprinzi, E. A. Perez, B. A. Mincey, A. Tan, K. Burger, C. Zhao, B. Diekmann and J. A. Sloan. Endpoint Comparison for Bone Mineral Density Measurements in North Central Cancer Treatment Group Cancer Clinical Trials N02C1 and N03CC (Alliance). *Osteoporosis International*. 2015 Mar 7 [Epub ahead of print]. PubMed PMID: 25749740; PubMed Central: In process at NIHMS 681319. (Study ID: N02C1 and N03CC)
- Kulkarni, A. A., G. Boora, R. Kanwar, K. J. Ruddy, M. S. Banck, N. Le-Lindqwister, T. M. Therneau, C. L. Loprinzi and A. S. Beutler. RWDD3 and TECTA variants not linked to paclitaxel induced peripheral neuropathy in North American trial Alliance N08C1. *Acta Oncol*. 2014 Dec 31 [Epub ahead of print]: 1-3. PubMed PMID: 25549536; PubMed Central: PMCTBD. (Study ID: N08C1)
- Park, H., R. Qin, T. J. Smith, P. J. Atherton, D. L. Barton, K. Sturtz, S. R. Dakhil, D. M. Anderson, K. Flynn, S. Puttabasavaiah, N. A. Le-Lindqwister, G. D. A. Padula and C. L. Loprinzi. North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. *Menopause*. 2015 Jun; 22(6): 000-000. PubMed PMID: 25423327; PubMed Central: In process at NIHMS 629808. (Study ID: N10C2)
- Wagner-Johnston, N. D., J. A. Sloan, H. Liu, A. Kearns, S. L. Hines, S. Puttabasavaiah, J. M. Lafky, E. A. Perez and C. L. Loprinzi. 5 year Follow-up of a Randomized Controlled Trial of Immediate versus Delayed Zoledronic Acid for Prevention of Bone Loss in Postmenopausal Women with Breast Cancer Starting Letrozole after Tamoxifen- N03CC. *Cancer*. Accepted 1/9/2015. PubMed PMID: TBD; PubMed Central: In process at NIHMS 671288. (Study ID: N03CC)

## Abstracts (11):

- Arnold, K., R. Andridge, A. Logan, L. Yee, M. Lustberg and T. Orchard. Healthy Eating Index Scores are Associated with Inflammatory Markers in Breast Cancer Survivors. The FASEB Journal. 2015 April 1, 2015; 29(1 Supplement): LB267. Poster Discussion.  
[http://www.fasebj.org/gca?allch=&submit=Go&gca=fasebj%3B29%2F1\\_Supplement%2FLB267](http://www.fasebj.org/gca?allch=&submit=Go&gca=fasebj%3B29%2F1_Supplement%2FLB267). (Study ID: Pilot Project NCT01478477; Alliance-funded pilot)
- Himelstein, A. L., R. Qin, P. J. Novotny, D. K. Seisler, J. L. Khatcheressian, J. D. Roberts, C. L. Loprinzi and C. L. Shapiro. CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. ASCO Annual Meeting May 29-June 2, 2015. Oral Presentation. (Study ID: 70604)
- Iott, M. J. Primary and secondary endpoint analysis of N08C9 (Alliance): A phase III randomized study of sulfasalazine versus placebo in the prevention of acute radiation enteritis. J Clin Oncol (Meeting Abstracts) January 2015; 33(3\_suppl): 562.  
[http://meeting.ascopubs.org/cgi/content/abstract/33/3\\_suppl/562](http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/562). (Study ID: N08C9)
- Lustberg, M. B., T. Orchard, X. Pan, R. Reinbolt, A. Logan, J. Lester, R. M. Layman, E. Macrae, E. Mrozek, B. Ramaswamy, R. Wesolowski, M. Berger, M. Knopp, C. Loprinzi, C. L. Shapiro and L. Yee. Prevention of aromatase Inhibitor (AI)-induced joint symptoms with omega-3 fatty acid supplementation: A randomized placebo-controlled pilot study. San Antonio Breast Cancer Symposium December 8-12, 2014. Abstract nr P1-09-03. Poster Presentation.  
[http://www.abstracts2view.com/sabcs14/view.php?nu=SABCS13L\\_1076](http://www.abstracts2view.com/sabcs14/view.php?nu=SABCS13L_1076). (Study ID: Pilot Project NCT01478477; Alliance-funded pilot)
- Miller, R. C., D. G. Petereit, J. A. Sloan, H. Liu, J. A. Martenson, J. D. Bearden, R. Sapiente, G. R. Seeger, R. B. Mowat, B. Liem, M. J. Iott and C. L. Loprinzi. Primary and Secondary Endpoint Analysis of N08C9 (Alliance): A Phase 3 Randomized Trial of Sulfasalazine Versus Placebo in the Prevention of Acute Radiation Enteritis. International Journal of Radiation Oncology\*Biophysics\*Physics. 2014 September; 90(1, Supplement): S86. Oral Presentation.  
<http://www.sciencedirect.com/science/article/pii/S0360301614011274>. (Study ID: N08C9)
- Orchard, T. S., X. Pan, J. Lester, A. Logan, C. L. Shapiro, R. D. Jackson, M. A. Belury, L. Yee and M. B. Lustberg. Relationship of dietary and red blood cell polyunsaturated fatty acids to inflammatory markers in breast cancer survivors taking aromatase inhibitors. San Antonio Breast Cancer Symposium December 8-12, 2014. Abstract nr P1-09-30. Poster Presentation.  
[http://www.abstracts2view.com/sabcs14/view.php?nu=SABCS13L\\_1597](http://www.abstracts2view.com/sabcs14/view.php?nu=SABCS13L_1597). (Study ID: Pilot Project NCT01478477; Alliance-funded pilot)
- Orchard, T. S., M. A. Belury, R. Cole, R. Andridge, X. Pan, J. Lester, A. Logan, L. Yee and M. B. Lustberg. Formulating and Testing a Typical American Diet Mixture of Fats and Oils in a Softgel Capsule for Use as a Placebo in Randomized Controlled Trials. American Oil Chemists Society Annual Meeting May 3-6, 2015. Oral Presentation. (Study ID: Pilot Project NCT01478477; Alliance-funded pilot)
- Ruddy, K., D. R. Pachman, R. Qin, D. Seisler, E. M. Lavoie Smith, S. Puttabasavaiah, P. Novotny, L. E. Ta, A. S. Beutler, N. D. Wagner Johnston, N. Staff, A. Grothey, S. Dakhil and C. L. Loprinzi. A Comparison of the Natural History of Oxaliplatin- and Paclitaxel-Induced Neuropathy (NCCTG N08C1, N08CB/Alliance). ASCO Annual Meeting May 29-June 2, 2015. Poster Presentation. (Study ID: N08C1 and N08CB)

Ruddy, K. J., G. K. Boora, R. Kanwar, A. Kulkarni, R. Qin, D. Seisler, D. Pachman, A. Grothey, C. L. Loprinzi and A. S. Beutler. Validation of single nucleotide variants previously associated with oxaliplatin-induced peripheral neuropathy: NCCTG N08CB (Alliance) Association for Clinical and Translational Science Annual Meeting April 16-18, 2015. Poster Presentation. (Study ID: N08CB)

Zimmerman, C., P. Atherton, D. Pachman, D. Seisler, N. Wagner Johnston, S. Dakhil, J. M. Lafky, R. Qin, A. Grothey and C. L. Loprinzi. Venlafaxine to Prevent Oxaliplatin-Induced Neuropathy? A Pilot Randomized Placebo Controlled Trial. ASCO Annual Meeting May 29-June 2, 2015. Publication Only. (Study ID: Study ID: Pilot Project NCT01611155; Alliance-funded pilot)

Zimmerman, C., P. Atherton, D. Pachman, D. Seisler, N. Wagner Johnston, S. Dakhil, J. M. Lafky, R. Qin, A. Grothey and C. Loprinzi. Venlafaxine to Prevent Oxaliplatin-Induced Neuropathy? A Pilot Randomized Placebo Controlled Trial. MASCC/ISOO Annual Meeting June 25-27, 2015. Poster Presentation. (Study ID: Study ID: Pilot Project NCT01611155; Alliance-funded pilot)